FORT MYERS, Fla. , Sept. 24, 2024 /PRNewswire/ -- Clinical research findings utilizing real-world data and conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) will be shared with a pre-eminent global audience focused on advancing the diagnosis and treatment of multiple myeloma, a rare blood cancer and the second most common hematologic malignancy in the U.
S. The abstract, "Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma," will be presented at the International Myeloma Society 21 st Annual Meeting in Rio De Janeiro, Brazil . Co-authors of the abstract are Lucio N.
Gordan , MD , FCS president and managing physician, Amanda Warner , MS, BSN, RN, OCN, CAPM, FCS Director of Real-World Evidence, Gustavo Fonseca , MD, FACP , FCS medical oncologist and hematologist, Trevor Heritage , PhD , FCS senior vice president and data officer, and Amy Ming , FCS senior director of informatics. The research was conducted in partnership with Janssen Scientific Affairs, LLC. Dr.
Gordan said, "Although there is no cure for multiple myeloma, we are making steady progress to enhance the quality of life and outcomes for patients with this disease." "Our ability to tap real-world data derived from the treatment FCS provides to more than one million patients, combined with industry-leading data science, has a significant positive impact in our understanding of blood cancers.
